PURPOSE: To evaluate whether pretherapeutic serum soluble @entity5962 is an independent factor predicting long-term survival in @entity356 . @entity356 remains the second leading cause of @entity5 in the world, but a satisfactory @entity5 marker is currently unavailable for @entity356 . Soluble @entity5962 has recently been found to have prognostic value in @entity356 . @entity1 AND METHODS: One hundred sixteen @entity1 with histologically proven @entity356 were included in the trial. Pretherapeutic serum was collected, and soluble @entity5962 was assayed using a commercially available enzyme-linked immunosorbent assay kit. The @entity1 were followed up prospectively at the outpatient clinic. RESULTS: There were 75 @entity1 and 41 @entity1 , with a mean (+/- SD) age of 66 +/- 14 years. Forty-eight percent of @entity5 were located in the gastric antrum. The median survival time was 11 months. The mean pretherapeutic value of soluble @entity5962 was 9,159 ng/mL (range, 6,002 to 10,025 ng/mL), and the mean pretherapeutic level of carcinoembryonic antigen was 11 ng/mL (range, 0.3 to 4,895 ng/mL). On multivariate analysis, soluble @entity5962 is an independent factor predicting long-term survival. Ninety percent of @entity1 with a serum level of @entity5962 greater than 10,000 ng/mL had a survival time of less than 3 years (P =.009). CONCLUSION: Soluble @entity5962 is a potentially valuable pretherapeutic prognostic factor in @entity1 with @entity356 .

Soluble @entity5962 is an independent pretherapeutic factor for long-term survival in XXXX .

@entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancer-related deaths', 'tumors'] @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'PATIENTS', 'men'] @entity5962 :: ('999', 'Gene') :: ['E-cadherin'] @entity356 :: ('MESH:D013274', 'Disease') :: ['gastric cancer', 'gastric adenocarcinoma', 'Gastric cancer']
@entity356 :: (MESH:D013274,Disease) :: ['gastric cancer']
